# Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice

> **NIH NIH N01** · COLORADO STATE UNIVERSITY · 2022 · $1,250,319

## Abstract

Preclinical Services for HIV Therapeutics: The purpose of these Indefinite Delivery/Indefinite Quantity contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies or from collaborations with private sector or academic partners. The scope of work encompasses activities that range from basic research and initial product discovery to activities required for clinical trials and/or product licensure. These services may also be used to support product discovery and development leading to Investigational New Drug Application (IND), Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID Division of AIDS will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The focus of these contracts will be development of therapeutic products for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Mycobacterium tuberculosis (MTB) complex, as well as repository services. The purpose of this Task Order is to test standard Mycobacterium tuberculosis (Mtb) combination drugs in a small animal model of Mycobacterium tuberculosis.

## Key facts

- **NIH application ID:** 10696863
- **Project number:** 75N93021D00014-0-759302200001-1
- **Recipient organization:** COLORADO STATE UNIVERSITY
- **Principal Investigator:** RICHARD SLAYDEN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,250,319
- **Award type:** —
- **Project period:** 2022-09-01 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10696863

## Citation

> US National Institutes of Health, RePORTER application 10696863, Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice (75N93021D00014-0-759302200001-1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10696863. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*